

ENDO PHARMA LLC  
Form 4  
October 27, 2005

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ENDO PHARMA LLC

2. Issuer Name and Ticker or Trading Symbol  
ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
320 PARK AVENUE  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
10/26/2005

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
\_\_X\_\_ 10% Owner  
\_\_\_\_ Other (specify below)

NEW YORK, NY 10022  
  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_X\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, par value \$.01 per share	10/26/2005		X	5,512 D	\$ 2.42	21,995,145	D
Common Stock, par value \$.01 per share	10/26/2005		X	1,743 D	\$ 2.42	21,993,402	D
Common Stock, par value \$.01 per share	10/26/2005		X	15,834 D	\$ 2.42	21,977,568	D

Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	10/26/2005	X	1,286	D	\$ 2.42	21,976,282	D
Common Stock, par value \$.01 per share	10/26/2005	X	3,972	D	\$ 3	21,972,310	D
Common Stock, par value \$.01 per share	10/26/2005	X	1,256	D	\$ 3	21,971,054	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	10/26/2005		X	5,512	10/13/2005 08/26/2007	Common Stock 5,512
Call Option (obligation to sell)	\$ 2.42	10/26/2005		X	1,743	10/13/2005 08/26/2007	Common Stock 1,743
Call Option (obligation to sell)	\$ 2.42	10/26/2005		X	15,834	10/13/2005 08/26/2007	Common Stock 15,834
Call Option (obligation to sell)	\$ 2.42	10/26/2005		X	1,286	10/13/2005 08/26/2007	Common Stock 1,286
Call Option (obligation to sell)	\$ 3	10/26/2005		X	3,972	10/13/2005 08/26/2007	Common Stock 3,972

to sell)

Call Option  
(obligation  
to sell)

\$ 3

10/26/2005

X

1,256

10/13/2005

08/26/2007

Common  
Stock

1,256

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022		X		

## Signatures

/s/ Jeffrey R. Black Chief Financial  
Officer

10/27/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.